All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
During the MPN Hub Steering Committee Meeting in May 2024, key opinion leaders met to discuss the place of bone marrow transplant (BMT), and BMT reporting consistency. Alessandro Vannucchi delivered a presentation on use of BMT in myelofibrosis (MF), including strategies to optimize the outcomes of BMT and considerations to be made for special populations.
Reconsidering the place of bone marrow transplant (BMT), and BMT reporting consistency
Vannucchi discusses the increase trend for the use of allogenic hematopoietic stem cell transplant (allo-HSCT) in patients as well as the age of patients with MF who may be eligible. They highlight the importance of considering the risks and benefits of transplant, consideration comorbidities, and early transplant where possible. They also highlight how to optimize transplant outcomes, discussing the role of splenomegaly and management, as well as post-transplant monitoring. This presentation concludes with a discussion on the impact of TP53 mutations and accelerated vs blast phase MF in special populations.
Following their presentation, Vannucchi chaired a Q&A session featuring Steering Committee members Laura Michaelis, Haifa Kathrin Al-Ali, Tiziano Barbui, Steffen Koschmieder, Chloe James, and guest speaker Benjamin Rolles. Discussions include how mutations, such as ASXL1, may impact selecting BMT and ruxolitinib in the first line, and how it could be used prior to BMT to prevent GvHD.
Reconsidering the place of BMT, and BMT reporting consistency: Q&A session
Your opinion matters
Thrombotic and hemorrhagic complications in MPN
Thrombotic and hemorrhagic complications in MPN
Thrombotic and hemorrhagic complications in MPN
Thrombotic and hemorrhagic complications in MPN
Subscribe to get the best content related to MPN delivered to your inbox